 | Up a level |
Journal Article
Al-Batran, S-E., Hofheinz, R. D., Schmalenberg, H., Strumberg, D., Goekkurt, E., Angermeier, S., Zander, T., Potenberg, J., Kopp, H-G., Pink, D., Siegler, G. M., Schenk, M., De Vita, F., Maiello, E., Gaiser, T., Sookthai, D., Bankstahl, U. S., Pauligk, C., Goetze, T. O. and Homann, N. (2020). Perioperative FLOT plus ramucirumab versus FLOT alone for resectable esophagogastric adenocarcinoma- Updated results and subgroup analyses of the randomized phase II/III trial RAMSES/FLOT7 of the German AIO and Italian GOIM. Ann. Oncol., 31. S. S901 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Schliemann, C., Pink, D., Floercken, A., Ahrens, M., Egerer, G., Goetze, K., Palmerini, E., Stacchiotti, S., Grignani, G., Rutkowski, P., Ullrich, R., Strapatsas, J., Hemmerle, T., Neri, D. and Kessler, T. (2021). A phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patients with advanced or metastatic soft tissue sarcoma. Ann. Oncol., 32. S. S1127 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041